Evidence map›Paper›PMID 34297345›Full record

ReviewCurrent obesity reports2021

Benefits of Low Carbohydrate Diets: a Settled Question or Still Controversial?

Matthew J Landry, Anthony Crimarco, Christopher D Gardner

Open access · greenAbstract readReview
In one paragraph

Review in Current obesity reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Edible Potential ofFood science & nutrition · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Matthew J LandryStanford Prevention Research Center, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0003-2285-7702
Anthony CrimarcoStanford Prevention Research Center, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID https://orcid.org/0000-0002-4553-4589
Christopher D GardnerStanford Prevention Research Center, School of Medicine, Stanford University, Palo Alto, CA, USA. cgardner@stanford.edu.
Stanford University · USStanford Medicine · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
CARDIOVASCULAR DISEASE PREVENTION TRAINING PROGRAMT32HL007034 · NHLBI · STANFORD UNIVERSITY · PI GARDNER, CHRISTOPHER D · 1985 to 2020
$8.7M
NHLBI NIH HHS T32 HL007034NIDDK NIH HHS P30 DK116074
6 · The paper itself

Abstract

purpose of reviewThe purpose of this review was to provide an update on the available data on the benefits of low-carbohydrate (low-carb) diets for weight management and type 2 diabetes (T2DM) and determine if low-carb diets were a settled question or still controversial. RECENT

findingsMost of the recent published literature in this area consists of reviews of past trials, with a relatively smaller number of recent trials. Low-carb is most commonly compared to low-fat, with problematically inconsistent definitions of both. There are numerous challenges in trying to draw clear conclusions about efficacy and effectiveness. Short-term vs. long-term effects can differ, which is likely impacted by adherence. Adherence is very different between metabolic chamber or feeding studies vs. free-living. Body weight alone is a crude measure that fails to capture potentially important differences in lean-mass, fat-mass, and body water. Benefits for glycemic control need to be balanced with impacts on non-glycemic outcomes such as LDL-cholesterol, the microbiome, and inflammation. It is important to differentiate between low-carb and very-low carbohydrate diets (VLCD). To date no large-scale long-term clinical trials have been conducted testing whether low-carb diets can prevent T2DM. Many issues regarding benefits and risks of low-carb diets remain controversial or unresolved, particularly for VLCD. Some of the recent, better studies highlighted in this review suggest strategies for resolving these controversies.

Indexed as

Diabetes Mellitus, Type 2Body WeightDietary CarbohydratesDiet, Carbohydrate-RestrictedHumansDietary CarbohydratesKetogenicLow carbohydrateNarrative reviewType 2 diabetesVery low carbohydrateWeight management

Identifiers

PMID34297345
PMCPMC9621749
OpenAlexW3183924568

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.